Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PLC Systems -- Ignore unavailable to you. Want to Upgrade?

To: Mark J Trudeau who wrote (562)	3/5/1998 9:21:00 AM
From: Rob C.	Respond to of 1202

Mark, Time to take it out and wack-it....lol, buckle up because the PLC shuttle is getting ready for lift-off. This news is what the big boys are waiting for. Regards, Rob

To: Mark J Trudeau who wrote (562)	3/5/1998 11:25:00 AM
From: Rob C.	Respond to of 1202

Mark, DOW JONES Headline - Story to Follow PLC Heart Laser to be reviewed. 15 today??? Regards, Rob

To: Mark J Trudeau who wrote (562)	3/5/1998 11:40:00 AM
From: Rob C.	Read Replies (1) \| Respond to of 1202

Thursday March 5, 11:15 am Eastern Time Company Press Release SOURCE: PLC Systems Inc. TMR Using PLC Systems' Heart Laser Will be Reviewed by a Food and Drug Administration Advisory Panel on April 24, 1998 FRANKLIN, Mass., March 5 /PRNewswire/ -- PLC Systems Inc. (Amex: PLC - news) today announced that a Food and Drug Administration (FDA) Advisory Panel will review Transmyocardial Revascularization (TMR) using The Heart Laser(TM) System on April 24, 1998. Announcement of the review date is available on the FDA information line. William C. Dow, President and CEO of PLC Systems Inc., stated, ''PLC was able to successfully complete the collection and analyses of the 12 month data from the controlled-randomized study of TMR using The Heart Laser System as requested by the July 28, 1997 FDA panel. We believe this data continues to support the benefits of TMR using PLC's laser and look forward to the panel's review.'' Written notification of the circulatory system devices advisory panel meeting is expected to be posted in the Federal Register approximately 30 days prior to the meeting. All FDA advisory panel schedules are subject to change. TMR, or transmyocardial revascularization uses The Heart Laser(TM) System, a high-powered, computer controlled carbon dioxide (CO2) laser to create channels into oxygen deprived heart muscle of coronary artery disease patients. Although the exact mechanism of action is unknown, some researchers believe these channels provide blood directly from the left ventricle to the deprived areas of the heart muscle, while others believe some form of angiogenesis also occurs. Recovery is generally quicker than that following bypass surgery. No blood transfusion is needed and, since the procedure is performed on a beating heart, there is no need for a heart-lung machine. The characteristics of The Heart Laser System surgery offer the potential of cost savings for the hospital and increased quality of life for the patient. PLC Systems Inc. is a cardiac revascularization company developing medical systems and technology with the potential to provide patients suffering from coronary artery disease an alternative or adjunct to angioplasty and cardiac bypass surgery. PLC Medical Systems, Inc., a wholly-owned subsidiary of PLC System Inc., has developed the high-powered CO2 Heart Laser system which uses the Company's patented technology for a new cardiosurgical procedure known as Transmyocardial Revascularization (TMR). To date, more than 3,500 patients worldwide have received treatment with The Heart Laser(TM) system. NOTE: Certain of the statements may be forward looking statements that involve risks and uncertainties. In such instances, actual results could differ materially as a result of a variety of factors including competitive developments, no guarantee of FDA approval and other risk factors listed from time to time in the Company's SEC reports. SOURCE: PLC Systems Inc.